%5b1%5d.jpg&h=570&w=855&q=100&v=20170226&c=1){kind=logo}
Invida is a leading specialty biopharmaceutical company in Asia-Pacific with over 3,500 employees across 13 countries.
Atopiclair is a new class of atopic dermatitis flare-remission treatment that has been found to be effective and safe for infants, children and adults.
Commenting on the appointment, Sumeet Sud, Invida chief marketing officer, said, “Saatchi & Saatchi clearly demonstrated they could not only offer healthcare communication expertise but could bring intimate understanding of our target audience beyond the healthcare professionals – the mothers themselves.”
“We are excited that an organisation of Invida's scale and scope has put its confidence in us to partner with them on the growth of the Atopiclair brand across the region. It is a validation of the extensive consumer research we undertook to understand how mothers and healthcare professionals feel about atopic dermatitis and its treatment. This has led us to the creation of a powerful idea for Atopiclair that will resonate to both target audiences across the region," added Celevel Ranoco-Butler, general manager of Saatchi & Saatchi Singapore.
.jpg&h=334&w=500&q=100&v=20170226&c=1)
.jpg&h=334&w=500&q=100&v=20170226&c=1)
.png&h=334&w=500&q=100&v=20170226&c=1)
.png&h=268&w=401&q=100&v=20170226&c=1)
.jpg&h=268&w=401&q=100&v=20170226&c=1)
